GLPwatch
A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
Curr Diab Rep · 2016
Last updated 2026-05-28There are six GLP-1 drugs approved for type 2 diabetes, including three short-acting options taken daily (exenatide, liraglutide, lixisenatide) and three long-acting options taken weekly (exenatide, albiglutide, dulaglutide). All of these drugs improve blood sugar control, but they differ in effects on weight loss, how they control blood sugar after meals, their impact on heart health, and side effects like stomach issues or injection reactions.
AI summary of the abstract below.
| Journal | Curr Diab Rep, 2016 |
|---|---|
| Citations | 13 |
| Relative citation ratio | 0.54 |
| NIH percentile | 31 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease |
Abstract
Incretin-based therapies are important addition to our armamentarium for the treatment of type 2 diabetes (T2DM). There are six Glucagon-like peptide-1 receptor agonists (GLP-1RAs) which have received regulatory approval for clinical use. The short-acting GLP-1RAs include exenatide twice daily, liraglutide once daily, and lixisenatide once daily. The approved long-acting GLP-1RAs are administered weekly and are exenatide, albiglutide, and dulaglutide. Although all of these therapies lower hemoglobin A1C (HbA1C), there also are unique features of GLP-1RAs that have been made manifest from clinical trial data with regard to weight-loss efficacy, fasting and post-prandial glucose control, cardiovascular safety and protection, and gastrointestinal and injection adverse effects. It is imperative to consider these features when tailoring the choice of a GLP-1RA to patient specific characteristics.
Verbatim abstract via PubMed 27766579 ↗